恩替卡韦对于失代偿期乙肝肝硬化患者肝功能的影响  

Entecavir impact studies for decompensated liver function in cirrhotic patients with hepatitis B

作　　者：任贺庄[1] 高金保[1] 高凤成[1] 

机构地区：[1]榆林市第一医院消化内科,陕西榆林71900

出　　处：《黑龙江医药科学》2015年第2期68-69,71,共3页Heilongjiang Medicine and Pharmacy

摘　　要：目的：研究恩替卡韦对于失代偿期乙肝肝硬化患者肝功能的影响。方法：选取2011-07~2013-10本院收治的80例失代偿期乙型肝炎肝硬化患者作为研究资料,随机分为研究组和对照组各40例,研究组患者在常规治疗的基础上加用恩替卡韦治疗,对照组患者仅接受常规治疗,对照两组患者的肝功能、凝血功能及Child-Pugh评分等指标。结果：两组患者治疗12、24周的肝功能水平均较治疗前出现显著改善,组间比较,研究组患者治疗12、24周的AST、ALT及TB水平均显著低于对照组患者同期,ALB水平显著高于对照组患者同期。两组患者治疗12、24周的凝血功能指标均较治疗前显著改善,研究组患者治疗12、24周的各指标均显著低于对照组患者同期水平。两组患者治疗前Child-Pugh评分无显著差异,研究组患者治疗12、24周的Child-Pugh评分显著低于对照组患者同期水平,两组患者在不良反应方面无显著差异。结论：恩替卡韦可以更为有效抑制乙肝病毒复制,改善失代偿期乙肝肝硬化患者的肝功能。Objective： To study the entecavir impact on decompensated cirrhosis of liver function in patients with hepatitis. Methods： 80 cases of patients with decompensated cirrhosis selected from July 2011 to October2013 in our hospital as research data were randomly divided into study group and control group with 40 cases in each. Patients in the study group were used entecavir treatment on the basis of conventional therapy. Patients in control group received only conventional treatment. Patients＇ indicators of liver function,blood clotting function,Child- Pugh scores and others were compared between two groups. Results： Liver function levels in both two groups were significantly improved after 12 and 24 weeks treatment. In study group,patients＇ levels of AST,ALT and TB after 12 and 24 weeks were significantly lower than those of patients in the control group,and the ALB level was significantly higher than that in control group. Coagulation parameters in both two groups were improved significantly. Each index in study group after 12 and 24 weeks was significantly lower than that in control group. Before treatment,the Child- Pugh scores were of no significant difference. After 12 and 24 weeks,the Child- Pugh score in study group was significantly lower than that in control group. In terms of adverse reactions,there was no significant difference between two groups. Conclusion： Entecavir can be more effectively suppress HBV replication and improve liver function decompensated liver cirrhosis patients.

关 键 词：恩替卡韦 失代偿期乙肝肝硬化 肝功能 

分 类 号：R575.2[医药卫生—消化系统]